Ishares Msci Italy ETF vs Liquidia Corporation Common Stock — how do they compare? Ishares Msci Italy ETF trades at $56.06 (market cap $1.20B), while Liquidia Corporation Common Stock trades at $33.78 (market cap $2.40B). The key difference: Liquidia Corporation Common Stock is far larger — about 2× Ishares Msci Italy ETF's market cap, and Ishares Msci Italy ETF is trading nearer its 52-week high, Liquidia Corporation Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ishares Msci Italy ETF for 55 Days and Liquidia Corporation Common Stock for 0 Days on average.
| EWI | LQDA | |
|---|---|---|
Market Cap | $1.20B | $2.40B |
Volume | 332,777 | 2,857,547 |
Sector | Broad Market / Factor | Health |
52-Week High | $63.35 | $91.03 |
52-Week Low | $50.47 | $22.02 |
Typical Hold Time | 55 Days | 0 Days |
Enterprise Value | — | $2.30B |
Signals from Pluang's Aura AI — not financial advice
EWI, the iShares MSCI Italy ETF, trades at $56.66 with a 0.87% daily gain. Technical indicators show a bearish trend with moving averages signaling strong selling pressure, though oscillators are neutral with RSI levels suggesting potential oversold conditions. The ETF offers concentrated exposure to Italian financials, utilities, and industrials, benefiting from sector consolidation and EU-supported infrastructure investments.
The outlook remains cautious due to eurozone economic pressures and ECB tightening, but EWI provides strategic access to Italy's banking and infrastructure investment cycle. Key risks include eurozone business confidence declines and energy price volatility. Analyst sentiment is mixed with technical weakness offset by long-term structural opportunities in Italian markets.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
EWI is a country-specific ETF that tracks the performance of the Italian equity market. It provides targeted access to large and mid-sized companies in Italy, with a heavy focus on the financial sector and holdings like UniCredit and Intesa Sanpaolo.
Read more on EWI →Liquidia Corporation is a biopharmaceutical company that develops therapies for rare cardiopulmonary diseases, including YUTREPIA, an inhaled treprostinil powder for pulmonary hypertension built on its PRINT technology.
Read more on LQDA →